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Abstract
Objective: The objective of this selective EBM review is to determine whether or not “Is
amitriptyline effective in reducing headache days in pediatric patients with migraines and
chronic headaches compared to topiramate, propranolol, or no treatment?”
Study design: Systematic review of two randomized control trials (RCTs) and one case series
published in peer-reviewed journals in English after 2007.
Data Sources: Two RCTs and one case series were found using PubMed.
Outcome(s) Measured: Headache frequency was measured using a headache diary or calendar.
A secondary objective included headache severity that was measured using a ten-point scale or
the Pediatric Migraine Disability Assessment (PedMIDAS).
Results: Powers et al. found that headache frequency did not vary significantly between
amitriptyline, topiramate, or placebo.2 It was also recorded that there was no significant variation
among reduction in scores on the PedMIDAS.2 Eidlitz-Markus et al. stated that this trial showed
no significant difference between amitriptyline and propranolol(p-value=0.8).4 Sezer et al. found
that 31% of patients in the topiramate group and 28% of patients in the amitriptyline group
“reported freedom from headache.”5 It was also recorded that the severity of headaches also
decreased 4.5 points on a visual analog scale in both treatment groups.
Conclusions: Amitriptyline in these three trials is less effective in reducing the frequency of
chronic headaches and migraines when compared to topiramate, propranolol, or a placebo.2,4,5
These results could be affected by subjectivity, drug adherence, or misunderstanding between
younger subjects and their parents. The safety of amitriptyline should always be in question
because the FDA warns that antidepressants can cause suicidal thoughts or actions in children
under eighteen years old.
Key Words: pediatric, migraine, headache, amitriptyline
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Introduction
Migraines are primary throbbing headaches of moderate or severe intensity that are
worsened by activity and associated with photophobia and/or phonophobia. These can be
accompanied by vomiting and abdominal pain. The pathophysiology is unclear. The most studied
and most recent theory is migraines are caused by cortical spreading depolarization across the
brain which can be associated with the aura before a migraine. This depolarization leads to
trigeminovascular system activation, causing increased activity in pain pathways. Migraines can
affect patients of all ages but studies show most children with migraines will have them
lifelong.1,2 They are more common in males in younger populations but more common in
females overall.1,2 Less than 25% of boys and 15% of girls have migraines before reaching age
fourteen.1 Altogether, more than 6 million children in the U.S. have migraines.2,3 These costs for
all patients of all ages are approximately $36 billion.2 Unfortunately, there is no way, other than
clinically, to diagnose migraines in any population. Acute treatment of migraines includes
analgesics (such as acetaminophen, ibuprofen, and naproxen), migraine-specific medications
commonly called “triptans” (such as sumatriptans, almotriptan, zolmitriptan or rizatriptan), or IV
dihydroergotamine. Preventative treatment of migraines includes antiepileptics (such as
topiramate or valproic acid), antihypertensives (such as flunarizine or propranolol),
antihistamines (such as cyproheptadine), and antidepressants (such as amitriptyline or
nortriptyline).
Chronic headaches are primary headaches that occur fifteen or more days each month for
three or more consecutive months. These headaches have different characteristics than
migraines. Chronic headaches are not throbbing and are not associated with photophobia or
phonophobia but they can be just as incapacitating as migraines. There may be overlap in
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patients with chronic headaches who also have a history of migraines.5 Both types of headaches
affect school performance but migraines alone are associated with higher deficiencies and
abscences.3,4 Studies and practitioners use the Pediatric Migraine Disability Assessment Scale
(PedMIDAS) to measure the debilitating effects of headaches on “school, home, play, and social
activities,”2
There is no single pharmacologic therapy suggested for the prevention of chronic
headaches or migraines in patients under eighteen. As with most diagnoses, pediatric patients are
tried on lower doses of treatments shown to provide relief in adults. These treatments are
complicated even more by the dosing difference in patients under twelve. Children older than
twelve should be treated with adult dosing. Most pediatric treatment strategies are based on
studies in adults. Amitriptyline is an oral tricyclic antidepressant used frequently for migraine
and chronic headache prevention in adults. Children older than twelve can take adult dosing but
younger children should take 1mg/kg/day (max 200mg/day). Amitriptyline inhibits serotonin
reuptake throughout the central nervous system. The theory behind this preventative strategy is
to prevent the low serotonin conditions that lead to an increase in pain receptor pathways during
trigeminovascular activation.
This paper evaluates two double-blind, RCTs and one case series comparing the efficacy
of amitriptyline with either topiramate, propranolol, or no treatment for reducing headache days
in pediatric patients diagnosed with chronic headaches or migraines.
Objective
The objective of this selective EBM review is to determine whether or not “Is
amitriptyline effective in reducing headache days in pediatric patients with migraines and
chronic headaches compared to topiramate, propranolol, or no treatment?”
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Methods
The author concluded all research by reviewing studies that analyzed the effectiveness of
amitriptyline. Two double-blinded RCTs and one case series surrounding female and male
participants younger than nineteen diagnosed with chronic headaches or migraines were chosen
for this selective review.
Amitriptyline was compared to different interventions, such as topiramate, propranolol,
or no treatment, in efficacy of reducing the frequency of headache days during each specified
trial period. Trial periods varied from 4 months to 24 weeks.2,5 The frequency of headache days
throughout each study was measured using a headache calendar or diary. A secondary goal was
to reduce headache severity. This was recorded via a ten-point scale or the PedMIDAS.
All articles were found via PubMed using the key words: pediatric, migraine, headache,
and amitriptyline. The author conducted all research for this review and carefully selected
articles that were both relevant and patient-oriented. The inclusion criteria for this review
encompassed articles that were primary research studies published between 2007 and the present,
all subjects were diagnosed with chronic headaches or migraines, and one trial group must be
treated with amitriptyline. Exclusion criteria for this review omitted articles that were not in
English, not peer-reviewed, and articles with subjects older than eighteen. Statistics were
reported using p-values and CI. After narrowing down studies with inclusion and exclusion
criteria, the author evaluated the relevance and validity of all articles.

Hall, Amitriptyline and Migraines 4

Table 1: Demographics of included studies
Study

Type

Powers
(2017)2

Double
blinded
RCT

EidlitzMarkus
(2012)4

Sezer
(2013)5

Case
series

Double
blinded
RCT

#of
Pts
361

118

60

Age
(yrs)
8-17

4-18

12-16

Inclusion criteria

Exclusion criteria

W/D

Interventions

Diagnosis of migraine
with/without aura or
chronic migraine
without continuous
headache as defined
by the International
Classification of
Headache Disorders,
2nd edition
A score on the
PedMIDAS from 11
to 139
A headache
frequency of >4 days
from a prospective
headache diary over a
baseline period of 28
days
Pediatric patients
ages 4.4 to 18 with
either chronic or
episodic migraine
headaches making
non-pharmacological
lifestyle changes

No exclusion criteria
listed

64

Amitriptyline
1mg/kg/day
PO

Pediatric patients
with chronic daily
headache including
chronic migraines

Topiramate
2mg/kg/day
PO
Placebo

Inability to verbally
communicate pain
Failure to adhere to
full instructions for
treatment
Failure to maintain
regular follow-up
Overusing prescribed
medication
Parental refusal of
pharmacologic
treatment
Symptoms of
increased intracranial
pressure, neurological
abnormalities as
revealed by clinical
examination or brain
MRI
The presence of
systemic diseases and
major psychiatric
disorders (depression)
The current use of
high-dose analgesics
Previously used
amitriptyline or
topiramate

N/a

Amitriptyline
10-25 mg/day
PO QHS
Propranolol 580 mg/day PO
BID

3

Amitriptyline
0.5 mg/kg PO
Topiramate
100 mg/day
PO
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Outcomes measured
The frequency of headache days in all three studies was recorded by way of individual
calendar or diary entries by subjects or their parents. An outcome of greater than 50% reduction
in headache frequency was presented in all studies and is seen in Table 2. The secondary
objective noted in two studies was to reduce headache baseline severity. Powers et al. measured
severity using the PedMIDAS.2 Sezer et al. measured headache severity using a ten-point visual
analog scale (VAS) in which 10 indicates most severe and 1 indicates least severe.5
Results
This review compares the efficacy of amitriptyline to similar migraine prevention
methods in three different studies. Powers et al. compared 1mg/kg/d of amitriptyline to 2mg/kg/d
of topiramate or placebo.2 Patients were included in the study if they had a previous diagnosis of
any type of migraine with or without aura except continuous migraine as defined by the
International Classification of Headache Disorders, 2nd edition, a PedMIDAS score 11-139 or a
headache frequency more than four days during the baseline period (twenty-eight days) before
the study.2 In this twenty-four week trial the reduction in headache days from baseline to the end
of the trial was -6.7 days (95% CI, -7.9 to -5.5) with amitriptyline and -6.7 days (95% CI, -7.6 to5.7) with topiramate. The placebo had very similar results causing an early end to the trial due to
the ineffectiveness of the trial’s pharmacologic interventions (Table 2).2 Reduction of headache
severity was calculated by comparing the PedMIDAS score during the baseline period and the
post-treatment score. There was no significant difference in reduction of disability scores when
comparing any two treatment methods (Table 3).2
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Table 2: Greater than 50% reduction in headache frequency
Study
Powers (2017)2

Amitriptyline
52%

Eidlitz-Markus (2012)4
Sezer (2013)5

82.2%
55%

Comparison group(s)
55% topiramate
61% placebo
85% propranolol
61% topiramate

Table 3: PedMIDAS scores2
Treatment
comparison
Amitriptyline Topiramate
Placebo
Topiramate
Placebo

Difference in score pre-treatment to posttreatment
4.5
-0.4
-4.8

P-value
0.10
0.91
0.13

Eidlitz-Markus et al. compared 0.266-0.4mg/kg/d of amitriptyline to 0.47-0.81mg/kg/d of
propranolol.4 Patients were included in the study if they were under age eighteen, were diagnosed
chronic or episodic migraine headaches, and were making “non-pharmacologic lifestyle
changes.”4 Children were excluded from the study if they were unable to verbally express their
pain to parents or staff, if caregivers or subjects were unable to follow instructions for treatment
or follow-up, if subjects overused treatment methods of any type of medication, or if parents
refused treatments for the subjects.4 The results of this trial showed no significant difference
between the different treatment options (p-value=0.8) (Table 2).4 The dosage of each medication
was titrated throughout the trial to attempt to increase drug effectiveness. After subjects’ dosage
of propranolol had reached 0.81mg/kg/d without efficacy, treatment was switched from
propranolol to amitriptyline.4 In the propranolol treatment group, 72% of subjects without aura
saw 75% or more decrease in headache frequency as compared to 28% of subjects with aura (pvalue=0.02).4 The same association was not seen in the amitriptyline group.
Sezer et al. compared 0.5mg/kg of amitriptyline to 100mg/d of topiramate.5 Children
were selected for this trial if they were age 12-16 with chronic daily headache.5 This
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encompasses patients with chronic migraine. Sezer et al. stated children were excluded from the
trial if they had “symptoms of increased intracranial pressure, neurological abnormalities as
revealed by clinical examination or brain MRI, the presence of systemic diseases, major
psychiatric disorders including depression, and the current use of high-dose analgesics or
previously used amitriptyline or topiramate.”5 This article reports after four months of treatment,
28% of patients treated with amitriptyline “reported freedom from headache.”5 Which was less
than the 31% of patients treated with topiramate who reported the same (p-value>0.05).5 The
severity of headaches decreased 4.5 points on the VAS after treatment for both amitriptyline and
topiramate (p-value>0.05).5
As seen in Table 2, the reduction in headache frequency is evident. In a final analysis, the
reduction in frequency is slightly higher in comparison groups. According to the numbers needed
to treat (NNT) in Table 3 for all three articles, patients would see benefits with other trial
medications or placebos than with amitriptyline. The NNT for each article was below zero. From
the study by Powers et al. amitriptyline is compared to placebo in Table 3.2
Table 4: Number Needed to Treat (NNT) or Harm (NNH)
Study
Powers (2017)2
Eidlitz-Markus
(2012)4
Sezer (2013)5

RRR
-0.15

ARR
-0.09

NNT
-11.11-11

-0.04

-0.028

-35.7-35

-0.10

-0.06

-16.66-16

RRI

ARI

NNH

N/a

0.01

100

The safety of amitriptyline will come into question for all pediatric patients.
Unfortunately, amitriptyline was associated with significant adverse events in four patients such
as altered mood, and syncope (Table 4).2 The FDA has always cautioned against using
antidepressants in patients under eighteen years old for risk of suicidal thoughts or actions.
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Discussion
There are a significant amount of studies covering of the benefits and risks of
amitriptyline in adult populations.6 Studies in pediatric populations regarding any treatment
method are scarce. This became a limitation of the author’s searching. Future studies should
encompass more pediatric double-blind, randomized control trials.
One limitation of most studies was the lack of investigation into compliance. Only one
study checked compliance of patients and their parents by testing serum drug levels.2 The
outcomes of these studies could vary significantly if families were reporting use but were not
following dosing or other directions.
Powers et al. concluded the study early due to futility.2 There is a significant amount of
evidence from the 24 week trial and continuing the study would not have produced new
information on the benefits or risks of amitriptyline, topiramate, or placebo.2 Powers et al. has
shown to be very thorough due to its baseline survey over 28 days and the comparison of this
baseline to the last 28 days of the study.
Every medication has side effects on the body. Amitriptyline’s primary side effects are
changes in behavior or thinking, dry mouth, and fatigue. All of these mental and anticholinergic
side effects were reported in the study by Powers et al.2 It is primarily prescribed for major
depressive disorder but has many off-label uses in adults. In children, the only uses are for the
treatment of depression, chronic pain management, and migraine prophylaxis.
Conclusion
Tricyclic antidepressants such as amitriptyline is effective in treating adults with chronic
headaches and migraines but it appears to be ineffective in children.6 Amitriptyline, in all three
trials, was less effective in reducing the frequency of chronic headaches and migraines when
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compared to topiramate, propranolol, or a placebo.2,4,5 These outcomes may be affected by the
subjectivity of results collection. The documentation on headache calendars or diaries was
recorded at home by pediatric patients or their parents which may have been affected by
improper documentation. These outcomes may also have been affected by patient drug
adherence. Fortunately, this was combatted by close follow up during the trials and serum-drug
level testing by Powers et al. Future studies should include more testing for adherence. Some
documentation was by parents whose children had limited communication skills.4 These parents
may have misinterpreted their child’s signs further skewing results of the trial. Further studies
should be conducted comparing different dosages of amitriptyline due to the variation amongst
the studies selected for this review. Overall, more studies are required to decrease the instance
and severity of migraines and headaches in pediatric populations.
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